Considering the profound impact of HIF-1α on cancer progression, there has been vast growing interest in the biology of the HIF-1α pathway and in the development of direct or indirect HIF-1 inhibitors for cancer therapy [14–17]. This evidence concerns the gene SETD2 and cancer.